News Snapshot:
Aug. 6 (UPI) -- British drugmaker AstraZeneca said Thursday it has an agreement with a Chinese company to produce 100 million doses of its COVID-19 vaccine, when completed, in China by the end of this year. AstraZeneca said in a post to Chinese social platform WeChat that it has a deal with Shenzhen-based vaccine manufacturer BioKangtai to license Astra's investigatory AZD1222 candidate, which it's developing in a partnership with Oxford University. Advertisement Under the partnership, AstraZenica will provide the initial 100 million doses this year and as many as 200 million doses by the end of 2021. It also specifies...
